Veloxis announces FDA approval of treatment for kidney transplants
Veloxis Pharmaceuticals A/S last week announced the U.S. Food and Drug Administration approved Envarsus XR for the prophylaxis of rejection in kidney transplant patients who require or want change from other twice-daily tacrolimus products to once-daily Envarsus XR. Read More »